Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal
BioPharma Drive: Drug Pricing
JUNE 5, 2025
A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two targets of interest in inflammatory conditions.
Let's personalize your content